US 12,447,194 B2
Composition for diagnosing, preventing, or treating cognitive dysfunction comprising COTL1 as active ingredient
Seon Yong Jeong, Yongin-si (KR); and Eunkuk Park, Suwon-si (KR)
Assigned to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Appl. No. 17/777,464
Filed by AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
PCT Filed Nov. 19, 2020, PCT No. PCT/KR2020/016329
§ 371(c)(1), (2) Date May 17, 2022,
PCT Pub. No. WO2021/101257, PCT Pub. Date May 27, 2021.
Claims priority of application No. 10-2019-0149076 (KR), filed on Nov. 19, 2019; and application No. 10-2020-0155079 (KR), filed on Nov. 19, 2020.
Prior Publication US 2023/0355710 A1, Nov. 9, 2023
Int. Cl. A61K 38/17 (2006.01); A61P 25/28 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)
CPC A61K 38/1709 (2013.01) [A61P 25/28 (2018.01); C12Q 1/6883 (2013.01); G01N 33/6896 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/2814 (2013.01)] 1 Claim
 
1. A method for treating cognitive dysfunction comprising administering an effective amount of a pharmaceutical composition comprising a gene encoding a coactosin-like 1 (COTL 1) protein as an active ingredient to a subject in need thereof,
wherein the cognitive dysfunction is selected from the group consisting of dementia, Parkinson's disease, learning disorder, agnosia, amnesia, aphasia, Pick disease, mild cognitive impairment, and Binswangers disease.